相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis
Stephen P. McAdoo et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2019)
Evaluation of PR3-ANCA Status After Rituximab for ANCA-Associated Vasculitis
Mark E. McClure et al.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY (2019)
Association Between Reappearance of Myeloperoxidase-Antineutrophil Cytoplasmic Antibody and Relapse in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Subgroup Analysis of Nationwide Prospective Cohort Studies
Haruki Watanabe et al.
ARTHRITIS & RHEUMATOLOGY (2018)
Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides
Benjamin Terrier et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
B cell therapy in ANCA-associated vasculitis: current and emerging treatment options
Mark McClure et al.
NATURE REVIEWS RHEUMATOLOGY (2018)
Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2)
Pierre Charles et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis
Emma E. van Daalen et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Detection of antineutrophil cytoplasmic antibodies (ANCAs): a multicentre European Vasculitis Study Group (EUVAS) evaluation of the value of indirect immunofluorescence (IIF) versus antigen-specific immunoassays
Jan Damoiseaux et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis
Xavier Bossuyt et al.
NATURE REVIEWS RHEUMATOLOGY (2017)
Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial
Seerapani Gopaluni et al.
TRIALS (2017)
EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis
M. Yates et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Factors Determining the Clinical Utility of Serial Measurements of Antineutrophil Cytoplasmic Antibodies Targeting Proteinase 3
Lynn A. Fussner et al.
ARTHRITIS & RHEUMATOLOGY (2016)
Current and novel biomarkers in anti-neutrophil cytoplasm-associated vasculitis
Juliana Bordignon Draibe et al.
CLINICAL KIDNEY JOURNAL (2016)
Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial
Rachel B. Jones et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
ANCA as a Predictor of Relapse: Useful in Patients with Renal Involvement But Not in Patients with Nonrenal Disease
Michael J. Kemna et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2015)
Accurate Relapse Prediction in ANCA-Associated Vasculitis-the Search for the Holy Grail
Ulrich Specks
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2015)
Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease
J. Charles Jennette et al.
NATURE REVIEWS RHEUMATOLOGY (2014)
Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis
L. Guillevin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Efficacy of Remission-Induction Regimens for ANCA-Associated Vasculitis
Ulrich Specks et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's) Ten-year experience at a single center
Rodrigo Cartin-Ceba et al.
ARTHRITIS AND RHEUMATISM (2012)
Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis
Rona M. Smith et al.
ARTHRITIS AND RHEUMATISM (2012)
Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis-a meta-analysis
Gunnar Tomasson et al.
RHEUMATOLOGY (2012)
Incidence and Prevention of Bladder Toxicity From Cyclophosphamide in the Treatment of Rheumatic Diseases A Data-Driven Review
Paul A. Monach et al.
ARTHRITIS AND RHEUMATISM (2010)
Mycophenolate Mofetil vs Azathioprine for Remission Maintenance in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis A Randomized Controlled Trial
Thomas F. Hiemstra et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis.
John H. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis.
Rachel B. Jones et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis
P. A. Merkel et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Highly Sensitive B Cell Analysis Predicts Response to Rituximab Therapy in Rheumatoid Arthritis
Shouvik Dass et al.
ARTHRITIS AND RHEUMATISM (2008)
Azathioprine or Methotrexate Maintenance for ANCA-Associated Vasculitis.
Christian Pagnoux et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies
Richard Watts et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Serial ANCA determinations for monitoring disease activity in patients with ANCA-associated vasculitis: Systematic review
R Birck et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2006)
A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies
D Jayne et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Serial ANCA titers: Useful tool for prevention of relapses in ANCA-associated vasculitis
WK Han et al.
KIDNEY INTERNATIONAL (2003)
分享论文
